# DESCRIPTION

## BACKGROUND

- introduce HIV/AIDS
- describe cART
- motivate HIV-capsid as antiviral target
- describe CA protein structure
- describe CA protein function
- describe capsid core
- describe uncoating process
- describe nuclear entry
- describe integration of viral DNA
- describe viral assembly
- describe CA mutations
- describe CA interactions with host factors
- describe CA as antiviral target
- describe CA inhibitors
- motivate need for new antivirals

## SUMMARY

- introduce cyclic or linear peptide
- describe peptide sequence
- describe peptide variants
- describe peptide with additional amino acids
- describe peptide with dye, chelator, or radionuclide
- describe peptide binding to HIV-1 capsid protein
- describe peptide binding pocket
- describe peptide interaction with capsid protein residues
- describe peptide binding affinity
- describe peptide length and structure

## DETAILED DESCRIPTION

### Definitions

- define "a" or "an" entity
- define "and/or"
- define "comprising"
- define technical and scientific terms
- define numeric ranges
- define headings
- define "polypeptide"
- define "cyclic peptide"
- define "polar uncharged amino acid"
- define "hydrophobic amino acid"
- define "protein"
- define "isolated" polypeptide
- define "polynucleotide"
- define "isolated" nucleic acid
- define "sequence identity"
- define "vector"
- define "transformed" cell
- define "expression"
- define "gene product"
- define "treat" and "treatment"
- define "subject"
- define "pharmaceutical composition"
- define "effective amount"
- define "cyclic or linear peptide of this disclosure" and HIV-1 capsid "assembling" and "disassembling"

### Overview

- introduce GS-CA1-bound CA hexamer crystal structure
- report GS-CA1 binding site
- compare GS-CA1 with PF74, CPSF6, and NUP153
- describe GS-CA1 resistance mutations
- analyze GS-CA1 binding pocket conservation
- introduce GS-6207 and its differences from GS-CA1
- dock GS-6207 into CA crystal structure
- compare GS-6207 with GS-CA1 binding
- analyze K70 side chain conformation
- compare GS-CA1 with PF74/CA crystal structure
- analyze Q67H resistance mutation
- superpose GS-CA1, PF74, and BI-2
- analyze common binding mode
- compare GS-CA1 with CPSF6/CA and NUP153/CA crystal structures
- superpose GS-CA1, CPSF6, and NUP153
- analyze F321 and F1417 superposition
- compare GS-CA1 with CA/CAP-1, CA/BD, and CA/BM complexes
- analyze M66 and L69 interactions
- introduce CAP-1 and its binding site
- compare CAP-1 with GS-CA1 binding
- introduce BD and BM series compounds
- analyze V36T and G61E resistance mutations
- introduce Coumermycin A1 and its predicted binding site
- dock Coumermycin A1 into CA crystal structure
- analyze N74D and A105S resistance mutations
- introduce other small molecule inhibitors of CA
- compare compound 34 with GS-CA1 binding
- introduce compound C1 and its binding site
- analyze R132T resistance mutation
- introduce Ebselen and its binding site
- design cyclic peptide inhibitor (Pep-2-cyclic)
- dock Pep-2-cyclic into CA crystal structure
- determine binding affinity of CA with Pep-2-cyclic and PF74
- compare binding affinities of Pep-2-cyclic and PF74

### Cyclic Peptides

- define cyclic peptide sequence
- specify X1, X2, and X3
- provide alternative sequences
- specify additional amino acids
- describe modifications to sequence
- specify length of peptide
- describe additional components
- specify binding to HIV-1 capsid protein
- describe binding pocket
- specify binding affinity
- describe inhibitory activity
- specify method of production
- describe linear peptide precursor
- specify additional modifications
- describe pharmaceutical composition
- describe method of treatment

### Linear Peptides

- define linear peptide sequence
- specify X1, X2, and X3
- provide alternative sequences
- specify additional amino acids
- describe modifications to sequence
- specify length of peptide
- describe additional components
- specify binding to HIV-1 capsid protein
- describe binding pocket
- specify binding affinity
- describe inhibitory activity
- specify method of production
- describe C-terminal modifications
- specify additional modifications
- describe pharmaceutical composition
- describe method of treatment
- specify isolated polynucleotide
- describe vector
- describe host cell

## EXAMPLES

### Example 1

- prepare HIV-1 CA structure for docking

### Example 2

- perform docking simulations of GS-CA1, GS-6207, and CA-1

### Example 3

- perform docking simulations of designed peptide Pep-2-Cyclic

### Example 4

- synthesize peptide Pep-2-cyclic
- determine binding affinities of CA with Pep-2-cyclic and PF74
- fluorescently label CA-hexamers
- perform MST assays
- analyze MST data
- fit data to quadratic equation
- plot data using PRISM
- define arbitrary parameter A
- define Kd
- define [P] and [CA]
- define [CA0] and [P0]
- describe MST reaction mixtures
- load reaction mixtures into capillaries
- monitor thermophoresis
- analyze data using MO. Affinity software
- determine binding affinity of Pep-2-cyclic
- determine binding affinity of PF74
- compare binding affinities

